{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:13:46Z","timestamp":1790298826751,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-042469"],"award-info":[{"award-number":["INV-042469"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005370","name":"Gates Cambridge Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA260476"],"award-info":[{"award-number":["CA260476"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.celrep.2024.115140","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T01:45:12Z","timestamp":1736041512000},"page":"115140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nonhuman primate antigenic cartography of SARS-CoV-2"],"prefix":"10.1016","volume":"44","author":[{"given":"Annika","family":"R\u00f6ssler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Netzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninaad","family":"Lasrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayeshbhai","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"M\u00fchlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel H.","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kimpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5127-4659","authenticated-orcid":false,"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2024.115140_bib1","unstructured":"W.H.O. (2022). Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). Interim statement on the composition of current COVID-19 vaccines. https:\/\/www.who.int\/news\/item\/17-06-2022-interim-statement-on--the-composition-of-current-COVID-19-vaccines"},{"key":"10.1016\/j.celrep.2024.115140_bib2","unstructured":"W.H.O. (2023). Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). Statement on the antigen composition of COVID-19 vaccines. https:\/\/www.who.int\/news\/item\/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines"},{"key":"10.1016\/j.celrep.2024.115140_bib3","unstructured":"W.H.O. (2024). Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). Statement on the antigen composition of COVID-19 vaccines. https:\/\/www.who.int\/news\/item\/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines."},{"key":"10.1016\/j.celrep.2024.115140_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-022-04690-5","article-title":"Defining the risk of SARS-CoV-2 variants on immune protection","volume":"605","author":"DeGrace","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2024.115140_bib5","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/S1473-3099(23)00682-5","article-title":"Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1","volume":"23","author":"Lassauni\u00e8re","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib6","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","article-title":"Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure","volume":"24","author":"Yang","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib7","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(23)02397-8","article-title":"Omicron BA.2.86 cross-neutralising activity in community sera from the UK","volume":"402","author":"Willett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2024.115140_bib8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.vaccine.2024.03.007","article-title":"Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1","volume":"42","author":"Lasrado","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2024.115140_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.celrep.2024.115140_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJMc2215509","article-title":"Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373","volume":"388","author":"Alves","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib11","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.chom.2022.10.012","article-title":"Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history","volume":"30","author":"Wang","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2024.115140_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101349","article-title":"Antigenic evolution of SARS coronavirus 2","volume":"62","author":"Mykytyn","year":"2023","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.celrep.2024.115140_bib13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1637\/8740-032509-ResNote.1","article-title":"Use of antigenic cartography in vaccine seed strain selection","volume":"54","author":"Fouchier","year":"2010","journal-title":"Avian Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/infdis\/jiv367","article-title":"Antigenic Maps of Influenza A(H3N2) Produced With Human Antisera Obtained After Primary Infection","volume":"213","author":"Fonville","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib15","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.15585\/mmwr.mm7222a3","article-title":"Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.celrep.2024.115140_bib17","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1093\/infdis\/jiae174","article-title":"High Frequency of Prior SARS-CoV-2 Infection by Sensitive Nucleocapsid Assays","volume":"230","author":"Nkolola","year":"2024","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/laban1004-50","article-title":"The Ferret: An Animal Model to Study Influenza Virus","volume":"33","author":"Maher","year":"2004","journal-title":"Lab Anim."},{"key":"10.1016\/j.celrep.2024.115140_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl1722","article-title":"Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays","volume":"16","author":"M\u00fchlemann","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-024-00888-y","article-title":"Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera","volume":"9","author":"R\u00f6ssler","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.celrep.2024.115140_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00948-24","article-title":"Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1","volume":"98","author":"Wang","year":"2024","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2024.115140_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41392-020-00269-6","article-title":"Comparison of nonhuman primates identified the suitable model for COVID-19","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.celrep.2024.115140_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2","volume":"585","author":"Munster","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2024.115140_bib24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41422-020-0364-z","article-title":"Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques","volume":"30","author":"Shan","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.celrep.2024.115140_bib25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2024.115140_bib26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.celrep.2024.115140_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2024.115140_bib28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2641","article-title":"Prior infection with SARS-CoV-2 WA1\/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants","volume":"13","author":"Chandrashekar","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-023-00622-0","article-title":"Immunogenicity and protective efficacy of GBP510\/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques","volume":"8","author":"Jacob-Dolan","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.celrep.2024.115140_bib31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.cell.2022.03.024","article-title":"Vaccine protection against the SARS-CoV-2 Omicron variant in macaques","volume":"185","author":"Chandrashekar","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2024.115140_bib32","article-title":"Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques","volume":"4","author":"Yu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID's Role in Pandemic Response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly."},{"key":"10.1016\/j.celrep.2024.115140_bib34","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.21105\/joss.03773","article-title":"Nextclade: clade assignment, mutation calling and quality control for viral genomes","volume":"6","author":"Aksamentov","year":"2021","journal-title":"J.\u00a0Open Source Softw."},{"key":"10.1016\/j.celrep.2024.115140_bib35","author":"Bloom"},{"key":"10.1016\/j.celrep.2024.115140_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/science.adj0070","article-title":"Mapping SARS-CoV-2 antigenic relationships and serological responses","volume":"382","author":"Wilks","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.celrep.2024.115140_bib37","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2666-5247(22)00384-6","article-title":"Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1","volume":"4","author":"Mykytyn","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.celrep.2024.115140_bib38","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1038\/s41467-022-35312-3","article-title":"BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants","volume":"13","author":"R\u00f6ssler","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2024.115140_bib39","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMc2201607","article-title":"Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection","volume":"386","author":"R\u00f6ssler","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib40","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chom.2022.04.014","article-title":"Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2","volume":"30","author":"Evans","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2024.115140_bib41","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.immuni.2024.02.016","article-title":"Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans","volume":"57","author":"Tortorici","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2024.115140_bib42","doi-asserted-by":"crossref","first-page":"2300740","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300740","article-title":"Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023","volume":"29","author":"Jeworowski","year":"2024","journal-title":"Euro Surveill."},{"key":"10.1016\/j.celrep.2024.115140_bib43","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","article-title":"Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib44","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1016\/S1473-3099(24)00298-6","article-title":"Virological characteristics of the SARS-CoV-2 KP.2 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114520","article-title":"Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants","volume":"43","author":"Li","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2024.115140_bib46","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1038\/s41467-023-41049-4","article-title":"Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography","volume":"14","author":"R\u00f6ssler","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2024.115140_bib47","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.immuni.2022.07.018","article-title":"Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron","volume":"55","author":"van der Straten","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2024.115140_bib48","unstructured":"ECDC. Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe. SURVEILLANCE REPORT. Influenza virus characterisation. Summary Europe, February 2011. (2011). https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/media\/en\/publications\/Publications\/1103_Influenza_virus_characterisation_2011_March.pdf."},{"key":"10.1016\/j.celrep.2024.115140_bib49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2024.115140_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients\u2019 B Cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2024.115140_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6990","article-title":"Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals","volume":"13","author":"Kim","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl9605","article-title":"Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques","volume":"14","author":"He","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7404","article-title":"Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine","volume":"15","author":"Feng","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2024.115140_bib54","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/S1473-3099(23)00573-X","article-title":"Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86","volume":"23","author":"Yang","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib55","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"Planas","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2024.115140_bib56","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","article-title":"Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines","volume":"630","author":"Liang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2024.115140_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46025-y","article-title":"XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants","volume":"13","author":"Patel","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2024.115140_bib58","unstructured":"FDA (2024). Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/updated-covid-19-vaccines-use-united-states-beginning-fall-2024."},{"key":"10.1016\/j.celrep.2024.115140_bib59","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S1473-3099(24)00603-0","article-title":"Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination","volume":"24","author":"Happle","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2024.115140_bib60","series-title":"acorg\/mapping_SARS-CoV-2_antigenic_relationships_and_serological_responses: Mapping SARS-CoV-2 Antigenic Relationships and Serological Responses, First Release (v.1.0.0)","author":"Wilks","year":"2023"},{"key":"10.1016\/j.celrep.2024.115140_bib61","series-title":"acorg\/roessler_netzl_et_al2023: Manuscript accepted (v1.0.0)","author":"Netzl","year":"2023"},{"key":"10.1016\/j.celrep.2024.115140_bib62","doi-asserted-by":"crossref","first-page":"e0095323","DOI":"10.1128\/aac.00953-23","article-title":"Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance","volume":"68","author":"Strizki","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.celrep.2024.115140_bib63","doi-asserted-by":"crossref","unstructured":"Wilks S.H. Racmacs: R Antigenic Cartography Macros 2022. https:\/\/acorg.github.io\/Racmacs, https:\/\/github.com\/acorg\/Racmacs.","DOI":"10.32614\/CRAN.package.Racmacs"},{"key":"10.1016\/j.celrep.2024.115140_bib64","series-title":"ablandscapes: Making Antibodz landscapes Using R","author":"Wilks","year":"2021"},{"key":"10.1016\/j.celrep.2024.115140_bib65","unstructured":"Team, C. (2021). R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org."},{"key":"10.1016\/j.celrep.2024.115140_bib66","series-title":"R Interface to \u2018CmdStan","author":"Gabry","year":"2022"},{"key":"10.1016\/j.celrep.2024.115140_bib67","author":"Kassambara"},{"key":"10.1016\/j.celrep.2024.115140_bib68","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.celrep.2024.115140_bib69","author":"Wickham"},{"key":"10.1016\/j.celrep.2024.115140_bib70","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J.\u00a0Open Source Softw."},{"key":"10.1016\/j.celrep.2024.115140_bib71","unstructured":"Pedersen, T.L. (2024). patchwork: The Composer of Plots. R package version 1.3.0. https:\/\/CRAN.R-project.org\/package=patchwork."},{"key":"10.1016\/j.celrep.2024.115140_bib72","series-title":"ggpubr: \u201cggplot2\u201d Based Publication Ready Plots_. R package version 0.6.0","author":"Kassambara","year":"2023"},{"key":"10.1016\/j.celrep.2024.115140_bib73","series-title":"GitHub repository.acorg\/roessler_netzl_et_al2024: Manuscript accepted (v1.0)","author":"Netzl","year":"2024"},{"key":"10.1016\/j.celrep.2024.115140_bib74","author":"Wilks"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124724014918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124724014918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:58:01Z","timestamp":1786219081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124724014918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2211124724014918"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2024.115140","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonhuman primate antigenic cartography of SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2024.115140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115140"}}